TORONTO, Oct. 14, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that
Alvaro Torres, Khiron CEO and
director, will present live at the Benzinga Virtual Cannabis
Capital Conference on October 15,
2020
Date:
|
Thursday, October 15,
2020
|
Time:
|
CPG panel at 2:00pm
ET
|
|
Solo presentation at
4:00pm ET
|
To register:
https://events.benzinga.com/squeeze-page-422415971598541487748
|
The Benzinga Virtual Cannabis Capital Conference, the
premier gathering for investors and entrepreneurs in the cannabis
industry, brings together hundreds of cannabis traders, investors,
entrepreneurs, and influencers to discuss the present and future
landscape of this evolving industry. Attendees enjoy exclusive
access to curated networking and private deal flow, as well as hear
from executives of top-performing cannabis companies leading the
way in growth and innovation.
Khiron CEO and Director Alvaro
Torres will present and take questions from conference
attendees in real time, and a recording of the session will be
available for those who cannot attend live on the event day.
Recent Company Highlights
- Reached more than 3,500 medical cannabis prescriptions
filled
- Medical cannabis prescriptions increased by over 450% in Q3,
compared to Q2 of 2020
- Clinics exceeded 9,000 monthly patient consultations in
September
- Khiron declared a National Strategic Project by the Government
of Colombia in September,
accelerating its ability to register and introduce new SKUs in the
medical cannabis and consumer-packaged goods categories
- First company to sell medical cannabis in Peru, introducing its new CBD brand
AlexinTM, sold under its previously announced agreement
with Farmacia Universal, the largest compounding pharmacy in
Peru
- Signed partnerships with 15 clinics and health centres in
Colombia, extending education and
sales reach further across the country
- Entered exclusive distribution agreement with Rappi SAS to
introduce and distribute the Company's CPG product portfolio across
Latin America through the Rappi
platform
- Signed a distribution deal with DNO Group to bring Company's
KuidaTM CBD cosmeceutical brand to retail and online
channels in Hong Kong
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution and sales, and
international export of both low and high THC medical cannabis
products. The Company has filled medical cannabis prescriptions in
Peru and has a presence in
Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-ceo-to-present-at-benzinga-virtual-cannabis-capital-conference-301152212.html
SOURCE Khiron Life Sciences Corp.